Long-Lasting Vascular Access for Patients on Dialysis

Long-Lasting Vascular Access for Patients on Dialysis Receives FDA Designation One of the first RMAT (regenerative medicine advanced therapy) designations from the US Food and Drug Administration has been awarded to Humacyl, an investigational human acellular vessel (HAV). Carrie Cox, CEO and chairman of Humacyte, the company that makes Humacyl, said the designation is an [Read More]

Get our newsletter for the latest news & updates.

Share the knowledge: